

# ***UPDATED* Executive Officer Notice: Ontario Naloxone Program for Pharmacies**

**Effective June 1, 2026**

This is an update to an earlier Executive Officer (“EO”) Notice dated May 5, 2025.

This notice provides information on updates to the Ontario Naloxone Program for Pharmacies (the “ONPP”).

This EO Notice and the accompanying Questions and Answers (“Qs and As”) set out the terms and conditions for a participating pharmacy’s submission of claims for payment under the ONPP. Each document is a ministry policy that pharmacy operators must comply with under section 3.2 of the Health Network System (HNS) Subscription Agreement for Pharmacy Operators.

Only Part A pharmacists and other authorized pharmacy staff<sup>1</sup> (acting under the supervision of a pharmacist who is physically present), can provide publicly funded naloxone kits to eligible individuals at participating pharmacies.

Prior to providing naloxone kits to eligible individuals, pharmacies must ensure that their Part A pharmacists and other authorized pharmacy staff are trained to provide the necessary training to eligible persons who are to receive the naloxone kits.

## **Overview of Changes**

Effective **June 1 2026** updates to the ONPP are as follows:

- Removal of the \$25 initial training fee for injectable naloxone kits and deactivation of PINs 93877251 and 93877257. Pharmacies must use PINs 93877252 and 93877258 when distributing injectable kits with naloxone ampoules or vials
- Addition of PINs 93877259 and 93877260 for the claim submission of a dual format kit (4 doses) containing one injectable kit (2 doses with the same DIN) and one intra-nasal kit (2 doses with the same DIN)

Additional updates include the following:

---

<sup>1</sup> References in this document to “other authorized pharmacy staff” refer to interns, Part A pharmacy technicians and intern technicians who are complying with the terms, conditions and limitations set out in Ontario Regulation 256/24 under the *Pharmacy Act, 1991*, as well as students who are in the course of fulfilling the educational requirements to become a member of the Ontario College of Pharmacists and who are authorized to dispense or sell drugs pursuant to a delegation under section 28 of the *Regulated Health Professions Act, 1991* (RHPA), or in accordance with clause 29(1)(b) of the RHPA. Please refer to this legislation for more information.

- Updated instructional insert in [English](#) and [French](#) that includes reference to the pre-filled syringe (PFS) format

## Pharmacy Eligibility

To be eligible to submit claims under the ONPP, a pharmacy operator (also referred to in this document as a “participating pharmacy”) must have a valid HNS Subscription Agreement with the ministry.

## Recipient Eligibility

The following individuals may receive eligible services (defined below) under the ONPP from participating pharmacies (“eligible individuals”):

- an individual who is at-risk of opioid overdose due to either currently using opioids or at-risk of returning to opioid use or
- a family member or friend, or other individual in a position to assist, an at-risk individual described above.

The individual does not need to be insured under the Ontario Health Insurance Plan (OHIP) or a recipient of the Ontario Drug Benefit (ODB) program. There is no cost to eligible individuals who receive eligible services under the ONPP, unless otherwise specified in this Notice.

## Eligible Services

Subject to the Exclusions and Restrictions below, a participating pharmacy **must** provide the following services (“eligible services”) to an eligible individual, in order to submit a claim for payment to the ONPP:

- The provision of a naloxone kit to the eligible individual within the physical premises of the pharmacy, subject to the limited exception below, based on an order from the eligible individual that is made in-person at the pharmacy or by telephone or videoconference conversation with a Part A pharmacist or other authorized pharmacy staff that is documented.

Exception: This requirement for the provision of the naloxone kit within the physical premises of the pharmacy does not apply if the eligible individual is already receiving care from the pharmacy and is unable to physically attend the pharmacy and requires the naloxone kit to be delivered to them at a valid address in Ontario. The participating pharmacy must ensure that the naloxone kit is picked up by a delivery agent for delivery to an eligible individual within ten (10) business days of accepting the eligible individual’s order for a naloxone kit.

- Where unforeseen and exceptional circumstances prevent the participating pharmacy from meeting the delivery timeline described above, pharmacies must ensure that the unforeseen and exceptional circumstances are documented as soon as possible following the expiry of the timeline.
- The provision of training to every eligible individual, every time they receive a naloxone kit. The training must be provided, on an individual basis, in *real-time*, and not in group settings. Training consisting solely of instructional videos, written materials (e.g. pamphlets), or websites is not permitted, but *real-time* virtual training may be provided.

Pharmacists are expected to use their professional judgement when providing naloxone kits to eligible individuals under the ONPP.

## Naloxone Kits Contents

The ministry does **not** procure naloxone kits and/or supplies for participating pharmacies but does mandate required kit contents.

Participating pharmacies can procure pre-made naloxone kits and/or the required supplies to assemble the naloxone kits (i.e., injectable and intra-nasal naloxone products) from their usual pharmacy suppliers and/or distributors.

Pharmacy-assembled naloxone kits must be assembled by a Part A pharmacist, or other authorized pharmacy staff acting under the supervision of a Part A pharmacist. Appendix A to this EO Notice lists the required items in a naloxone kit, with each kit containing 2 doses of naloxone (with the same DIN).

The Ontario Pharmacists Association (OPA) has developed resources relating to naloxone kits, including a listing of kit contents (<https://opatoday.com/naloxone-kit-supplies-list>), on their website at <https://opatoday.com/naloxone>.

## Billing Procedure

Pharmacies **must** submit claims for payment using the individual's valid Ontario health card number (if available), **on the same day** the naloxone kit(s) and training are provided. Reasonable efforts must be made to obtain the eligible individual's Ontario health card number.

If the eligible individual is a recipient of the Ontario Drug Benefit (ODB) program:

- Intervention code 'PS': Professional Care Services
- Product Identification Number (PIN): see Table 1 below for list of PINs

If the eligible individual is **not** an ODB program recipient and **has an Ontario health card number**:

- Patient Gender: 'F' = female; 'M' = male
- Patient Date of Birth: Valid YYYYMMDD
- Patient's Ontario Health number
- Intervention codes:
  - 'PS': Professional Care Services
  - 'ML': Established eligibility coverage (i.e., 1 day of the Plan 'S' coverage)
- Carrier ID: 'S'
- Product Identification Number (PIN): see Table 1 below for list of PINs

If the eligible individual is **not** an ODB program recipient and **does not have an Ontario health card number**, pharmacists must submit claims using a Proxy ID for payment:

- First Name: HARM
  - Last Name: REDUCTION
  - Patient Gender: 'F' = female; 'M' = male; (or) Blank
  - Patient Date of Birth: Valid YYYYMMDD (if known) or 20000101
  - Proxy patient ID: 89999 999 91
  - Intervention codes:
    - 'PS': Professional Care Services
  - Product Identification Number (PIN): see Table 1 below for list of PINs
- A valid Pharmacist ID is required in the prescriber field for all claim submission, this is the licence number of the Part A pharmacist who provides or supervises the provision of naloxone kits.
  - **Table 1** lists the claim submission PINs and the total amount payable for naloxone kits and training provided to each eligible individual by participating pharmacies, subject to the Exclusions and Restrictions below.
  - A maximum of **two (2) naloxone kits of any type (i.e., total 4 doses)** may be provided upon request to an eligible individual per day and **must be submitted as a single claim** for payment.
    - Note – **all** 4 doses for each of the 3 PINs listed below **must** be the same DIN, see Appendix A).
      - PIN 93877257 – Two injectable kits (ampoule or vial)
      - PIN 92877264 – Two injectable kits (pre-filled syringe)
      - PIN 93877262 – Two intra-nasal kits
  - **Effective June 1, 2026:** Pharmacies can submit claims for dual format kits (one injectable and one intra-nasal) with a single professional fee for **only** the combinations listed as follows. Note – A maximum of two (2) naloxone kits (i.e., total 4 doses) can be provided to an eligible individual per day submitted as a single claim using one of the following 2 PINs:

- PIN 93877259 – One injectable (ampoule or vial) kit containing 2 doses of the same DIN and one intra-nasal kit containing 2 doses of the same DIN
- PIN 93877260 – One injectable (pre-filled syringe) kit containing 2 doses of the same DIN and one intra-nasal kit containing 2 doses of the same DIN

**Table 1: Naloxone kits funded under the ONPP**

| PIN      | Naloxone Kit Type and Description  | Total Amount Paid |
|----------|--|-------------------|
| 93877252 | One Injectable Kit - <b>ampoule or vial</b> <ul style="list-style-type: none"> <li>• \$35 – cost of one kit</li> <li>• \$10 – professional fee</li> </ul>  | <b>\$45</b>       |
| 93877258 | Two Injectable Kits - <b>ampoule or vial</b> <ul style="list-style-type: none"> <li>• \$70 – cost of two kits</li> <li>• \$10 – professional fee</li> </ul>  | <b>\$80</b>       |
| 93877263 | One Injectable Kit - <b>pre-filled syringe</b> <ul style="list-style-type: none"> <li>• \$40 – cost of one kit</li> <li>• \$10 – professional fee</li> </ul>   | <b>\$50</b>       |
| 93877264 | Two Injectable Kits - <b>pre-filled-syringe</b> <ul style="list-style-type: none"> <li>• \$80 – cost of two kits</li> <li>• \$10 – professional fee</li> </ul>   | <b>\$90</b>       |
| 93877261 | One Intra-Nasal Kit <ul style="list-style-type: none"> <li>• \$64 – cost of one kit</li> <li>• \$10 – professional fee</li> </ul>  | <b>\$74</b>       |
| 93877262 | Two Intra-Nasal Kits <ul style="list-style-type: none"> <li>• \$128 – cost of two kits</li> <li>• \$10 – professional fee</li> </ul>   | <b>\$138</b>      |
| 93877259 | One injectable ( <b>ampoule or vial</b> ) kit and one intra-nasal kit (dual format) <ul style="list-style-type: none"> <li>• \$35 – cost of one injectable kit (ampoule or vial)</li> <li>• \$64 – cost of one intra-nasal kit</li> <li>• \$10 - professional fee</li> </ul>       | <b>\$109</b>      |
| 93877260 | One injectable ( <b>pre-filled syringe</b> ) kit and one intra-nasal kit (dual format) <ul style="list-style-type: none"> <li>• \$40 – cost of one injectable kit (pre-filled syringe)</li> <li>• \$64 – cost of one intra-nasal kit</li> <li>• \$10 – professional fee</li> </ul> | <b>\$114</b>      |

**Notes**

- **Do not** use the Drug Identification Number (DIN) of the naloxone product that is contained in the naloxone kit for claim submission.

## Pharmacy documentation requirements

Part A pharmacists, other authorized pharmacy staff and pharmacies shall keep records consistent with their obligations under the *Pharmacy Act, 1991*, the *Drug and Pharmacies Regulation Act*, and any instructions or guidelines provided by the Ontario College of Pharmacists or the ministry.

For purposes of post-payment verification, pharmacy records related to claims for naloxone distribution must be maintained in a readily available format for the purpose of ministry inspection for a minimum of 10 years from the last recorded pharmacy service provided to the patient, or until 10 years after the day on which the patient reached or would have reached the age of 18 years, whichever is longer, unless otherwise noted below.

For every naloxone kit distributed to an eligible individual under the ONPP, participating pharmacies must keep a record of service provision, including:

- The number and type of naloxone kit(s) provided and details of the training provided;
- Name and address of pharmacy where services were provided, signature of authorized pharmacy staff who provided the naloxone kit; and
- Date of service

If an eligible individual is unable to physically attend the pharmacy and requires the naloxone kit to be delivered to them at an Ontario address, participating pharmacies must keep additional documentation, including:

- Whether the order was placed by telephone or videoconference;
- The reason the individual is unable to physically attend the pharmacy;
- Date of the order, date on which the naloxone kit was picked up by the delivery agent for delivery to the eligible individual, and the date on which the naloxone kit was received by the eligible individual; and
- Any exceptional and unforeseen circumstances that prevented the pharmacy from giving the naloxone kit to a delivery agent for delivery to the eligible individual within the timeline described above.

In addition, reasonable efforts must be made to obtain the eligible individual's identity and contact information, including:

- Name, date of birth, and address of eligible individual,
- Ontario health card number of eligible individual

## Exclusions and Restrictions under the ONPP

Naloxone kits **cannot** be distributed to an eligible individual outside the physical premises of the pharmacy, unless the eligible individual is already receiving care from the pharmacy and is unable to physically attend the pharmacy, and requires the

naloxone kit to be delivered to them at an address in Ontario. Where this occurs, the eligible individual **must** order the naloxone kit from the pharmacy by telephone or videoconference and **must** speak in *real-time* with a Part A pharmacist or other authorized pharmacy staff. Pharmacy staff must offer *real-time* virtual training on the use of the naloxone kit. Training consisting solely of instructional videos, written materials (e.g., pamphlets), or websites is **not** permitted.

The following are **not** eligible for payment under the ONPP:

- Naloxone kits provided to businesses and/or organizations.
- Naloxone kits provided by in-patient hospital pharmacies.
- Claims for one (single) naloxone kit (PINs 93877252, 93877261 and 93877263) submitted twice in a day for an eligible individual as two kits. For clarity, only one naloxone kit PIN can be used per eligible individual per day.
- Naloxone kits that are ordered by recipients through a website or any electronic communication service other than a telephone or videoconference line that allows the eligible individual to speak in *real-time* with a Part A pharmacist or other authorized pharmacy staff. For clarity, the following electronic communication services **cannot** be used to accept or process orders: Short Message Service (SMS), social media platform, app, email, digital fax, and voicemail.

In addition:

- Only the cost of the kit (**without** the professional fee) is eligible for payment for residents of long-term care homes.
- A claim under the Pharmaceutical Opinion Program **cannot** be submitted for the recommendation for, and/or provision of naloxone kits.
- Overpayments due to inappropriate claim submissions are subject to recovery.

#### **Additional Information:**

##### **For pharmacy billing:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

##### **For inquiries relating to ONPP:**

Please email the ministry at: [PublicDrugPrgrms.moh@ontario.ca](mailto:PublicDrugPrgrms.moh@ontario.ca)

##### **For Ministry webpages relating to naloxone:**

Please access this [website](#)

##### **For all other Health Care Providers and the Public:**

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.

**APPENDIX A:**

Contents of the naloxone kits (both injectable and intra-nasal spray) are outlined below.

Each intra-nasal spray naloxone kit **must** include:

- One (1) zippered hard case with a “naloxone” cross
- Two (2) doses of naloxone hydrochloride intra-nasal spray 4 mg/0.1 mL (DIN 02511568, or DIN 02458187) (both doses must have the same DIN)
- One (1) rescue breathing barrier
- One (1) pair of non-latex gloves
- One (1) card that identifies the person trained to give the naloxone
- One (1) updated (2026) instructional insert ([English](#) and [French](#))

Each injectable naloxone kit **must** include:

- One (1) zippered hard case with a “naloxone” cross
- Two (2) alcohol swabs
- One (1) rescue breathing barrier
- One (1) pair of non-latex gloves
- One (1) card that identifies the person trained to give the naloxone
- One (1) updated (2026) instructional insert ([English](#) and [French](#))
- Either one of the following:
  - **Ampoule or Vial:**
    - Two (2) 1 mL ampoules or vials of naloxone hydrochloride injection 0.4 mg/mL (DIN 02453258, 02455935, or 02458578) (both doses must have the same DIN)
    - Two (2) safety engineered syringes with 25g x 1” (one inch) needles attached, as applicable
    - Two (2) safe ampoule-opening devices (also known as breakers, snappers, or openers), as applicable
  - **Pre-Filled Syringe:**
    - Two (2) 1mL 22G ½ needles of naloxone hydrochloride injection 0.4mg/mL (DIN: 02548194) (both doses must have the same DIN)